由出血性休克引起的器官功能障碍:从机制到治疗药物
Qingxia Huang1, Yisa Wang2, Zepeng Zhang1
1Research Center of Traditional Chinese Medicine, College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, Jilin 130021, China; Northeast Asia Research Institute of Traditional Chinese Medicine, Key Laboratory of Active Substances and Biological Mechanisms of Ginseng Efficacy, Ministry of Education, Jilin Provincial Key Laboratory of Bio-Macromolecules of Chinese Medicine, Changchun University of Chinese Medicine, Changchun, Jilin 130117, China.
出血性休克 (HS) 导致器官功能障碍. 针对免疫反应,氧化损伤和能量平衡的新药疗法显示,它有望改善HS患者的治疗结果.
科学领域:
- 关键护理医学 关键护理医学
- 药理学 药理学是指药理学的学科.
- 病理生理学 病理生理学
背景情况:
- 血流性休克 (HS) 是一种导致器官功能障碍和死亡率增加的危急状况.
- 目前对HS的辅助药物治疗缺乏广泛接受和强有力的证据,特别是对于血管压缩剂.
- 能量稳态的破坏和过度的免疫激活是驱动HS诱导器官功能障碍的关键机制.
研究的目的:
- 审查HS中器官功能障碍的病理生理学.
- 系统地评估潜在的治疗药物,针对HS的关键机制.
- 评估现有的药物与临床证据治疗HS诱导的器官功能障碍.
主要方法:
- 关于HS病理生理学和器官损伤机制的文献综述.
- 系统地搜索针对针对免疫,炎症,氧化应激,能量代谢和HS细胞死亡的药物的临床前和临床研究.
- 对HS诱导的器官功能障碍中药物的疗效临床证据的分析.
主要成果:
- 新兴的候选药物准免疫反应,氧化损伤和能量恒温.
- 通过最近的动物模型和临床试验,已经确定了几种潜在的治疗策略.
- 目前有限的临床证据支持HS的广泛辅助药物治疗.
结论:
- 了解HS引起的器官损伤机制对于开发向疗法至关重要.
- 专注于免疫力,氧化应激和能量代谢的新疗法可以缓解器官功能障碍并降低死亡率.
- 需要进一步的临床验证,以建立有效的辅助药物治疗出血性休克.
相关概念视频
Blood Pressure Imbalances and Circulatory Shock
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Introduction to Hemostasis
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...


